Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 2/20 | 0.45 |
| ▸ | CDK2 | P24941 | 2/20 | 0.45 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.45 |
| ▸ | ADK | P55263 | 6/20 | 0.44 |
| ▸ | GAPDH | P04406 | 1/20 | 0.44 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.44 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.44 |
| ▸ | HSPA8 | P11142 | 4/20 | 0.43 |
| ▸ | HSPA5 | P11021 | 2/20 | 0.43 |
| ▸ | CDK1 | P06493 | 1/20 | 0.43 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20973215 | 0.87 | GAPDH (0.48) | CCNA2CDK2CCNA1ADKGAPDH | |
| SCHEMBL20973489 | 0.85 | CDK5 (0.59) | CCNA2CDK2CCNA1ADKGAPDH | |
| SCHEMBL20973127 | 0.84 | CCNA2 (0.45) | CCNA2CDK2CCNA1ADKGAPDH | |
| SCHEMBL20973122 | 0.84 | ADK (0.47) | CCNA2CDK2CCNA1ADKGAPDH | |
| SCHEMBL21369235 | 0.79 | ADK (0.46) | CCNA2CDK2CCNA1ADKCDK5 | |
| SCHEMBL20973154 | 0.79 | ADK (0.61) | ADK | |
| SCHEMBL20973132 | 0.79 | ADK (0.69) | CCNA2CDK2CCNA1ADKGAPDH | |
| SCHEMBL19837973 | 0.77 | ADK (0.67) | CCNA2CDK2CCNA1ADKCDK5 | |
| SCHEMBL20973142 | 0.76 | ADK (0.48) | CCNA2CDK2CCNA1ADKGAPDH | |
| SCHEMBL21368890 | 0.76 | ADK (0.48) | ADKGAPDHCDK5CDK5R1HSPA8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190144487-A1 | SUBSTITUTED THIENOPYRROLOPYRIMIDINE RIBONUCLEOSIDES FOR THERAPEUTIC USE | USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I. (CZ) | 2019-05-16 | — | — | US | claimed |
| US-10414788-B2 | Substituted thienopyrrolopyrimidine ribonucleosides for therapeutic use | USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I. (CZ) | 2019-09-17 | — | — | US | disclosed |
| US-10414788-B2 | Substituted thienopyrrolopyrimidine ribonucleosides for therapeutic use | USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I. (CZ) | 2019-09-17 | — | — | US | disclosed |
| US-20190144487-A1 | SUBSTITUTED THIENOPYRROLOPYRIMIDINE RIBONUCLEOSIDES FOR THERAPEUTIC USE | USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I. (CZ) | 2019-05-16 | — | — | US | disclosed |
| US-20190144487-A1 | SUBSTITUTED THIENOPYRROLOPYRIMIDINE RIBONUCLEOSIDES FOR THERAPEUTIC USE | USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I. (CZ) | 2019-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190144487-A1 | SUBSTITUTED THIENOPYRROLOPYRIMIDINE RIBONUCLEOSIDES FOR THERAPEUTIC USE | TYMP, DPYD, TK2 | CCNA2 338/4885CDK2 990/4885CCNA1 558/4885 |
| US-10414788-B2 | Substituted thienopyrrolopyrimidine ribonucleosides for therapeutic use | TYMP, DPYD, TK2 | CCNA2 338/4885CDK2 990/4885CCNA1 558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.